Long-term comparison of platinum chromium everolimus-eluting stent vs. Cobalt chromium zotarolimus-eluting stent: 3-year outcomes from the HOST–ASSURE randomized clinical trial

HOST–ASSURE Investigators

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: There are limited data on the long-term outcome of platinum chromium-based everolimus-eluting stents (PtCr-EES) vs. cobalt chromium-based zotarolimus-eluting stents (CoCr-ZES). Methods and Results: A total of 3,755 patients undergoing percutaneous coronary intervention (PCI) were randomized 2:1 to PtCr-EES or CoCr-ZES, and 96.0% of patients completed the 3-year clinical follow-up. The primary outcome was target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR). At 3 years, TLF occurred in 5.3% and in 5.4% of the PtCr-EES and CoCr-ZES groups, respectively (hazard ratio 0.978; 95% confidence interval 0.730–1.310, P=0.919). There were no significant differences in the individual components of TLF. Routine angiographic follow-up was performed in 38.9% of the total patients. In a landmark analysis of the subgroup that had follow-up angiography, the clinically-driven TLR rate of CoCr-ZES was significantly higher than PtCr-EES group during the angiography follow-up period (P=0.009). Overall definite and probable stent thrombosis rates were very low in both groups (0.5% vs. 0.6%, P=0.677). Conclusions: PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population.

Original languageEnglish
Pages (from-to)1489-1497
Number of pages9
JournalCirculation Journal
Volume83
Issue number7
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Long-term comparison of platinum chromium everolimus-eluting stent vs. Cobalt chromium zotarolimus-eluting stent: 3-year outcomes from the HOST–ASSURE randomized clinical trial'. Together they form a unique fingerprint.

  • Cite this